Supplementary Table 1: Demographics of human post-mortem brain samples

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Subject no** | **Braak Stage** | **CERADa Score** | **APOEb Genotype** | **Age at Death** | **Gender** | **PMDd** | **Clinical Diagnosis** |
| Subject 1 | 0 | A | N/Ac | 90 | Male | 07:40 | Non-demented Control |
| Subject 2 | 0 | O | E3/E3 | 80 | Male | 07:15 | Non-demented Control |
| Subject 3 | 0 | B | E3/E3 | 88 | Female | 06:15 | Non-demented Control |
| Subject 4 | 1 | B | E3/E3 | 69 | Female | 15:30 | Non-demented Control |
| Subject 5 | 1 | A | E3/E3 | 87 | Male | 10:20 | Non-demented Control |
| Subject 6 | 5 | C | E3/E4 | 69 | Female | 05:45 | Alzheimer’s Disease |
| Subject 7 | 6 | C | E3/E4 | 89 | Female | 04:30 | Alzheimer’s Disease |
| Subject 8 | 6 | C | E4/E4 | 86 | Female | 05:00 | Alzheimer’s Disease |
| Subject 9 | 6 | C | E3/E4 | 94 | Female | 05:40 | Alzheimer’s Disease |
| Subject 10 | 6 | C | E3/E3 | 91 | Female | 03:40 | Alzheimer’s Disease |

aCERAD: Consortium to Establish a Registry for Alzheimer’s Disease

bAPOE: Apolipoprotein E

cN/A: Not available

dPMD: Post-mortem delay